Last reviewed · How we verify
NCT06228820: ART
Aspirin Resistance in Trinidad.
Phase 2 trial testing Aspirin 81Mg Ec Tab in Platelet Dysfunction Due to Drugs in 48 participants. Completed in 15 December 2024.
15 December 2024
Quick facts
| Lead sponsor | The University of The West Indies |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 15 January 2024 |
| Primary completion | 15 December 2024 |
| Estimated completion | 15 December 2024 |
| Sites | 1 location across Trinidad and Tobago |
Drugs / interventions tested
- Aspirin 81Mg Ec Tab — full drug profile →
Conditions studied
- Platelet Dysfunction Due to Drugs — all drugs for Platelet Dysfunction Due to Drugs →
Sponsor
The University of The West Indies
Who can join
Adults 18 to 74, any sex, with Platelet Dysfunction Due to Drugs. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aspirin's beneficial effect is mediated via the inhibition of arachidonic acid (AA) activation of platelets. It is detected by demonstrating a decrease in platelet function and/or a decrease in prostaglandin metabolites. Besides inhibiting the formation of thromboxane A2 from arachidonic acid, Aspirin has a host of platelet-independent effects that complement its platelet-inhibitory effects. The phenomenon of "Aspirin resistance" is based on the observation of clinical events in some patients taking Aspirin and/or a diminished platelet aggregation inhibitory response to Aspirin therapy. It has been suggested that many individuals taking Aspirin have become resistant to this drug. Unfortunately, laboratory assays used to monitor the efficacy of Aspirin are far from accurate, and the results are not reproducible. Multiple studies demonstrate non-compliance using repeat testing for platelet inhibition in patients with an initial inadequate response to Aspirin. When the test is repeated under the condition that the ingestion of the test Aspirin is assured, the patients' platelets are inhibited. Patients with an inadequate Aspirin response have an increased likelihood of subsequent vascular events.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacodynamic Comparison of Two Aspirin Formulations in the Caribbean: The ARC Study.
Seecheran N, McCallum P, Grimaldos K, Ramcharan P, et al · · 2024 · cited 1× · PMID 39008026 · DOI 10.1007/s40119-024-00373-6
Verify or expand the search:
- PubMed search for NCT06228820
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aspirin 81Mg Ec Tab
Trials testing the same drug.
- NCT05104229 — SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery · Phase 3 · withdrawn
- NCT05889468 — Postpartum ASA and NT-proBNP · Phase 4 · completed
- NCT05514847 — Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients · Phase 4 · active not recruiting
- NCT05009862 — The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Dis · Phase 4 · completed
- NCT04872283 — Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion · Phase 3 · unknown
Other The University of The West Indies trials
Trials by the same sponsor.
- NCT07177001 — Neck and Low Back Pain in Physical Therapy Students at The University of the West Indies, Mona, Jamaica · NA · not yet recruiting
- NCT07167888 — Low Back and Neck Pain in Nursing Students at The University of The West Indies · NA · not yet recruiting
- NCT07194746 — The Prevalence of Neck and Low Back Pain in FMSTRC Staff At the UWI Mona · NA · not yet recruiting
- NCT05856968 — Investigation of Continuous Versus Interrupted Subcutaneous Fat Closure in Reducing Surgical Site Infection · NA · not yet recruiting
- NCT05730244 — A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06228820 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of The West Indies
- Last refreshed: 12 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06228820.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing